Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal povidone-iodine for treatment of the common cold
ACTRN12619000764134Phase 3Completed
- Sponsor
- Firebrick Pharma
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngitis comparing Povidone-iodine nasal spray with Matching placebo nasal spray (2 arms). Primary endpoint: Nasal symptom score over Days 1-5. Started Jun 2019; status: completed.
02
Drugs
povidone-iodine
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on ACTRN12619000764134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000764134.